%0 Case Reports
%T Case report: Preventive infusion of donor-derived CD7 chimeric antigen receptor T cells after allogeneic hematopoietic stem cell transplantation.
%A Jiang Y
%A Feng D
%A Zhu J
%A Wei D
%A Zhao C
%A Liu H
%A Shao S
%A Wang C
%J Front Immunol
%V 15
%N 0
%D 2024
%M 38745670
%F 8.786
%R 10.3389/fimmu.2024.1381308
%X Chimeric antigen receptor T cells (CAR T) targeting CD7 for T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/LBL) showed promising efficacy and safety in some clinical trials. However, most of them were bridged with allogeneic hematopoietic stem cell transplantation (allo-HSCT). We described successful treatment with preventive donor-derived anti-CD7 CAR-T therapy in a case of refractory T lymphoblastic lymphoma following allo-HSCT, who could not receive autologous anti-CD7 CAR-T products due to the low-quality of T lymphocytes. To date, the patient's complete remission has persisted for 20 months after HSCT.